Selective activation of thyroid hormone signaling pathways by GC-1: A new approach to controlling cholesterol and body weight

John D. Baxter, Paul Webb, Gary Grover, Tom S. Scanlan

Research output: Contribution to journalReview article

90 Scopus citations


The current report describes progress in development of a selective thyroid hormone receptor modulator, GC-1. This compound binds selectively to the β-isoform of the thyroid hormone receptor, and its uptake into the heart is relatively low. Studies in rats, mice and monkeys show that GC-1 lowers cholesterol with 600- to 1400-fold more potency and approximately two- to threefold more efficacy than atorvastatin, a compound that blocks HMG-CoA reductase. GC-1 also decreases plasma levels of triglyceride and lipoprotein (a), and induces loss of fat. These effects can be observed under conditions where there is either no or minimal effect on heart rate, and no detectable loss of muscle. Although more study is required, compounds of this class deserve further investigation for treating lipid disorders and obesity.

Original languageEnglish (US)
Pages (from-to)154-157
Number of pages4
JournalTrends in Endocrinology and Metabolism
Issue number4
StatePublished - May 1 2004


ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this